Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Other Accumulated Expenses (2022 - 2026)

Lexeo Therapeutics' Other Accumulated Expenses history spans 2 years, with the latest figure at $554000.0 for Q4 2023.

  • On a quarterly basis, Other Accumulated Expenses rose 130.83% to $554000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $554000.0, a 130.83% increase, with the full-year FY2023 number at $554000.0, up 130.83% from a year prior.
  • Other Accumulated Expenses hit $554000.0 in Q4 2023 for Lexeo Therapeutics, up from $182000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for LXEO hit a ceiling of $554000.0 in Q4 2023 and a floor of $182000.0 in Q3 2023.